// App-Quantinova.ai

e17562 : Roles of an immune-check point inhibitor (nivolumab) in heavily pretreated and platinum-resistant gynecologic cancers.

Researchers

Presenter

  • Yoshihiro Kikuchi

Principal Investigators

  • Hiroko Kouta

  • Takayoshi Asakawa

  • Miyuki Horikoshi

  • Tomoyuki Yoshikawa

  • Masashi Takano

  • Kenichi Furuya

Medical Centers

  • Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Japan

  • Ohki Memorial Kikuchi Cancer Clinic for Women, Tokorozawa, Japan

  • Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Japan

  • Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Interleukin 6

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved